A New Class of 5-Fluoro-2′-deoxyuridine Prodrugs Conjugated with a Tumor-Homing Cyclic Peptide CNGRC by Ester Linkers: Synthesis, Reactivity, and Tumor-Cell–Selective Cytotoxicity

By Zhang Zhouen   Hatta Hiroshi   Tanabe Kazuhito   Nishimot o Sei-ichi  

Pharmaceutical Research, Vol. 22, Iss. 3, 2005-03 ,pp. : 381-389

Springer Publishing Company

Access to resources Recommend Favorite

Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice

By Xu Lu   Eiseman Julie L.   Egorin Merrill J.   D'Argenio David Z.  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 30, Iss. 3, 2003-06 ,pp. : 185-219

Springer Publishing Company

Access to resources Recommend Favorite

Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles

By Wang J.-X.   Sun X.   Zhang Z.-R.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 54, Iss. 3, 2002-11 ,pp. : 285-290

Elsevier

Access to resources Recommend Favorite

Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine

By Couto Diana   Ribeiro Daniela   Freitas Marisa   Gomes Ana   Lima José L. F. C.   Fernandes Eduarda  

Redox Report, Vol. 15, Iss. 6, 2010-12 ,pp. : 259-267

Maney Publishing

Access to resources Recommend Favorite

Pfizer's dual-acting β₂ agonists/muscarinic M₃ antagonists

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 9, 2008-09 ,pp. : 1091-1096

Informa Healthcare

Access to resources Recommend Favorite